EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss

Eion Plenn iD, Dylan Amin, Jonathan Henry, Gabrielle Leavitt, Jason Walker, Taraneh Soleymani

Obesity Science & Practice · 2025-08 · 11 (4)

DOI: 10.1002/osp4.70085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity Science & Practice, online erschienen am 06.08.2025. Verfasst von Eion Plenn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Penn State College of Medicine Hershey Pennsylvania USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Semaglutide 2.4 mg (Wegovy) is the first second‐generation anti‐obesity medication approved by the FDA for long‐term obesity treatment. Given the effectiveness of semaglutide 2.4 mg compared to first‐generation anti‐obesity medications and amid ongoing national shortages, understanding the real‐world experiences of individuals using semaglutide 2.4 mg is crucial. This qualitative study aims to explore the narratives of individuals using semaglutide 2.4 mg for weight management, as expressed in Reddit posts.

Methods

One thousand posts from the r/WegovyWeightLoss subreddit between October 10, 2022, and October 6, 2023, were retrospectively analyzed. After excluding irrelevant posts, 660 posts were included in the analysis. A codebook was collaboratively developed and data was coded using qualitative software. Themes were finalized and reviewed.

Results

Seven themes were identified from the analysis: medication efficacy (29.4% of coded posts), psychosocial impact of weight loss (22.8%), side effects management (13.3%), barriers to access (10.7%), lifestyle modification (10.2%), support and community (9.2%), and stigma surrounding use of semaglutide 2.4 mg for weight loss (4.4%).

Conclusion

This qualitative analysis of Reddit posts provides valuable insights into the real‐world experiences of individuals using semaglutide 2.4 mg for weight management. By understanding these user experiences, healthcare providers can better tailor obesity treatment plans and enhance patient‐centered care for those using second‐generation anti‐obesity medications like semaglutide 2.4 mg.

Schlagwörter

Stichwörter der Autor:innen

GLP‐1 receptor agonistsmental healthsemaglutide 2.4 mgweight stigma

Autor:innen und Institutionen

  • Penn State College of Medicine Hershey Pennsylvania USA.
  • St. George's University School of Medicine West Indies Grenada.
  • Cooper Medical School of Rowan University Camden New Jersey USA.
  • Lewis Katz School of Medicine Temple University Philadelphia Pennsylvania USA.
  • Geisinger Commonwealth School of Medicine Scranton Pennsylvania USA.

ORCID-Profile: Eion Plenn

Zitieren

APA

Plenn, E., Amin, D., Henry, J., Leavitt, G., Walker, J., & Soleymani, T. (2025). A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss. Obesity Science & Practice, 11(4). https://doi.org/10.1002/osp4.70085

Vancouver

Plenn E, Amin D, Henry J, Leavitt G, Walker J, Soleymani T. A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss. Obesity Science & Practice. 2025;11(4). doi:10.1002/osp4.70085

BibTeX
@article{Plenn2025,
  author = {Plenn, Eion and Amin, Dylan and Henry, Jonathan and Leavitt, Gabrielle and Walker, Jason and Soleymani, Taraneh},
  title = {A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss},
  journal = {Obesity Science & Practice},
  year = {2025},
  volume = {11},
  number = {4},
  doi = {10.1002/osp4.70085}
}
Kostenlos starten →